Elanco Animal Health reported second quarter 2026 results with revenue of $1,368 million, an increase of 10% year-over-year, and adjusted EPS of $0.34. The company raised its full-year 2026 guidance, increasing revenue expectations to $5.09 billion–$5.14 billion, adjusted EBITDA to $1.01 billion–$1.035 billion, and adjusted EPS to $1.10–$1.16. Elanco also updated its year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA, down from the current 3.1x. The firm operates in the animal health industry, developing and delivering products to prevent and treat disease in farm animals and pets.